Thymosin Alpha 1 (TA-1, brand name Zadaxin) is a synthetic 28-amino-acid immunomodulating peptide identical to a fragment naturally produced by the thymus gland. It is approved in 35+ countries for the treatment of hepatitis B, hepatitis C, and as adjuvant therapy for various cancers and immunocompromised conditions. Outside its approved indications, Thymosin Alpha 1 is used for general immune system support, post-illness recovery, and chronic infections. This guide covers Thymosin Alpha 1 benefits backed by clinical research, dosing protocols, side effects, and how it differs from other immune-supporting peptides.
Thymosin Alpha 1 is one of the few peptides with substantial Western clinical evidence, decades of off-label use in immunocompromised populations, and approval in major medical systems outside the US. It is not a “research peptide” in the same sense as Epitalon or BPC-157; it is a clinically validated immunomodulator with FDA orphan drug designation for some indications.
What Is Thymosin Alpha 1?
Thymosin Alpha 1 is a synthetic version of a peptide naturally produced by the thymus gland. The thymus is the central organ of T-cell development; it shrinks with age, contributing to the immunosenescence that increases susceptibility to infections, cancers, and autoimmune conditions in older adults.
Mechanism of action:
- T-cell maturation: stimulates differentiation of T-helper cells from immature precursors
- Th1 polarization: shifts immune response toward Th1 (cellular immunity), enhancing response to intracellular pathogens and tumors
- Dendritic cell activation: enhances antigen presentation
- NK cell activity: increases natural killer cell function
- Cytokine modulation: balances pro-inflammatory and regulatory cytokines
The net effect is a more responsive, balanced immune system without the broad immunosuppression of corticosteroids or the targeted suppression of biologic agents.
Approved Medical Uses
Thymosin Alpha 1 is approved in 35+ countries for:
- Chronic hepatitis B (alone or combined with interferon)
- Chronic hepatitis C (similar)
- Adjuvant cancer therapy in select tumor types
- Vaccine adjuvant in elderly populations
- Treatment of severe sepsis and immunocompromised states
In the US, FDA orphan drug designation exists for some indications but no full approval. The clinical evidence supporting these uses is robust by international standards but did not result in US FDA approval, partly due to lack of large US-based phase 3 trials.
Off-Label and Research Uses
Common off-label applications:
Chronic infections
Lyme disease, chronic viral infections (CMV, EBV, HHV-6), and chronic bacterial infections often respond to Thymosin Alpha 1 as adjunct therapy. The mechanism (immune modulation rather than direct antimicrobial) helps the body clear pathogens it has been struggling with.
Post-illness recovery
Long COVID, post-mono recovery, and other post-viral fatigue syndromes are common off-label use cases. Anecdotally, Thymosin Alpha 1 cycles produce measurable energy improvement in users with persistent post-illness symptoms.
Immune support during chemotherapy
Used as adjuvant to reduce infection risk and support immune function during cancer treatment. Cancer patients should always discuss with their oncologist before adding any immunomodulator.
General immune optimization
Older adults seeking immune resilience, frequent travelers, or users entering high-stress periods sometimes use Thymosin Alpha 1 cycles as preventive immune support.
Autoimmune conditions
Mixed evidence. Some autoimmune conditions improve (those driven by Th2 imbalance); others may worsen with immune stimulation. Consult specialist before use.
Thymosin Alpha 1 Dosing Protocol
Standard protocol:
- Dose: 1.6 mg subcutaneous, twice weekly
- Cycle length: 4 to 12 weeks depending on indication
- Frequency: 2 to 3 cycles per year for chronic immune support; longer continuous use for clinical conditions under medical supervision
For acute use (post-illness, during high-risk period):
- Loading: 1.6 mg daily for 5 days
- Maintenance: 1.6 mg twice weekly for 4 weeks
Reconstitution
Standard 5 mg vial:
- Add 1 mL bacteriostatic water → 5 mg/mL
- 1.6 mg dose = 0.32 mL (32 units on insulin syringe)
Refrigerate after reconstitution; stable 30 days. See our reconstitution guide.
Thymosin Alpha 1 Side Effects
One of the cleanest side effect profiles of any clinical peptide:
- Common: mild injection site reactions (redness, slight irritation), occasional mild fatigue in first few days
- Less common: temporary low-grade fever during initial dosing (consistent with immune activation)
- Rare: hypersensitivity reactions, autoimmune flare in susceptible individuals
No tolerance development. Compatible with most other medications. Decades of clinical use across millions of patient-treatment-courses with acceptable safety.
Thymosin Alpha 1 vs Other Immune Peptides
| Peptide | Primary effect | Best for | Evidence |
|---|---|---|---|
| Thymosin Alpha 1 | T-cell maturation, Th1 shift | Chronic infection, immune balance | Strong (clinical approval) |
| Thymosin Beta 4 (TB-500) | Tissue repair, anti-inflammation | Wound healing, recovery | Animal models |
| BPC-157 | Tissue repair, gut | Gut healing, joint repair | Animal models |
| Thymalin | Thymus support | General immune restoration in elderly | Russian clinical |
| LL-37 | Antimicrobial peptide | Antibiotic-resistant infections | Lab studies |
Thymosin Alpha 1 is distinct because it modulates rather than suppresses immune function. It is not interchangeable with TB-500 (Thymosin Beta 4); the names sound similar but the molecular structures and effects are different.
Who Should Consider Thymosin Alpha 1
- Users with chronic viral infections (post-COVID, chronic mono, shingles susceptibility)
- Users recovering from severe illness
- Older adults with frequent infections suggesting immune decline
- Cancer patients (with oncologist coordination)
- Users in high-stress periods who want preventive immune support
- Users with chronic bacterial infections (Lyme, etc.) as adjunct therapy
Who Should Avoid Thymosin Alpha 1
- Users with active autoimmune conditions where Th1 stimulation could worsen symptoms (rheumatoid arthritis flares, MS, lupus)
- Users on immunosuppressive medications for organ transplant
- Pregnant or breastfeeding women (limited safety data)
- Users with hypersensitivity to thymosin compounds
Thymosin Alpha 1 Stacking
Common combinations:
- Thymosin Alpha 1 + BPC-157: dual-pillar immune and gut support. Useful for users whose immune issues coincide with gut dysfunction.
- Thymosin Alpha 1 + Vitamin D3 + Zinc: pharmacological immune modulation paired with nutritional immune support.
- Thymosin Alpha 1 + Selank: immune support plus stress resilience for users dealing with chronic illness fatigue.
- Avoid stacking with multiple immune modulators simultaneously: produces unpredictable cytokine responses.
Common Thymosin Alpha 1 Mistakes
- Stopping too early: clinical effect requires 4 to 8 weeks of consistent dosing. Single doses produce no measurable change.
- Using during acute autoimmune flare: stimulating Th1 during an active flare can worsen symptoms. Wait for stable phase.
- Underdosing: 0.5 mg twice weekly produces minimal effect. Stick with 1.6 mg per dose for clinical-equivalent benefit.
- Combining with strong immunosuppressants: defeats the purpose. Coordinate with prescribing physician if on transplant or autoimmune medications.
- Skipping doses: protocol benefit requires consistency. Set reminders for the twice-weekly schedule.
Frequently Asked Questions
How long until Thymosin Alpha 1 works?
Subjective immune improvements typically appear at 2 to 3 weeks. Measurable changes in immune markers (T-cell counts, NK cell activity) take 4 to 6 weeks of consistent dosing.
Can I use Thymosin Alpha 1 for COVID prevention?
Limited specific evidence for COVID-19 prevention. Some Italian clinical trials during the 2020 pandemic suggested benefit in reducing severity in hospitalized patients. For prevention in healthy users, vaccines and basic precautions remain primary; Thymosin Alpha 1 is supplementary at best.
Is Thymosin Alpha 1 the same as TB-500?
No. Thymosin Alpha 1 (TA-1) and Thymosin Beta 4 (TB-500) are different molecules with different effects. Thymosin Alpha 1 is immune-focused; TB-500 is tissue repair-focused. See our TB-500 guide for the comparison.
Will Thymosin Alpha 1 cause my autoimmune condition to flare?
Possibly, depending on the condition. Th1-driven autoimmune conditions may improve; Th2-driven conditions may be unaffected; mixed-mechanism conditions are unpredictable. Consult specialist before use.
Can I use Thymosin Alpha 1 long-term?
Decades of clinical use suggest acceptable long-term safety. Most off-label users limit to 2 to 3 cycles per year (8 to 12 weeks each) with off-periods between.
Where can I get Thymosin Alpha 1?
For research-grade Thymosin Alpha 1 in Indonesia and Southeast Asia, see our pricelist. Order directly via WhatsApp.
This article is for informational and research-use purposes only. Thymosin Alpha 1 is approved for clinical use in 35+ countries but is not FDA-approved in the US. Always consult a qualified medical professional before starting any new protocol.